This trial seeks to enroll patients diagnosed with HER2-negative (HER2- low or HER2-0)- MBC who are starting treatment with T-DXd. The purpose is to determine if the test used for HER2+ MBC also works for HER2-low MBC. By participating in this trial, you are contributing to information that may improve the care of future patients with HER2-negative (HER2- low or HER2-0)- MBC. This trial does not require additional biopsies. Only tissue left over from a standard-of-care procedure will be used. The study team will access your medical record to review routine imaging test results as well as track your response to your treatment. Your breast cancer care will be managed by your oncologist, and you won't need to interact with the study team for direct care. No extra visits with the study team are required, except possibly for the initial enrollment.

Do you have early-stage breast cancer that is considered low-risk by your doctor? If yes, you might be able to join a research study. In this study, we are testing if taking a lower dose of the medicine tamoxifen is a better treatment for you than the usual hormone therapy.

Have you been diagnosed with Stage 4 HER2 positive (HER2+) breast cancer? If so, you may be able to take part in a research study to test the safety and effectiveness of a sequence of drugs (a taxane plus trastuzumab plus pertuzumab followed by trastuzumab Deruxtecan, followed by tucatinib plus Ado-trastuzumab emtansine (T-DM1), followed by trastuzumab plus pertuzumab plus tucatinib) to learn whether the treatment works in treating your type of cancer. The study will help us understand whether first intensifying therapy for a specific period and then stopping treatment is safe and effective for patients who receive this therapy.

Are you a woman with a history of breast cancer (Stage 0-III)? Do you identify as Black/African-American? Do you struggle with fear or worry that your cancer may return? If you are a breast cancer survivor that identifies as Black/African-American, you may be eligible to participate in the FoRtitude Interview Study. Compensation provided.

Have you been diagnosed with HER2-low locally unresectable advanced or metastatic breast cancer? If so, you may be eligible for a study to investigate the efficacy treatment with Dato-DXd or T-DXd.

Have you been diagnosed with Ovarian Cancer? Have you received cytoreductive surgery? If so, you may be able to take part in a study on a new ovarian cancer treatment. We want to find out if taking a medicine called Olaparib for one year works as well as the usual treatment for ovarian cancer. We also want to see if Olaparib can help stop the cancer from growing or coming back.

Have you been diagnosed with early stage triple negative breast cancer and not yet received treatment? If so, you may be eligible for a trial comparing the use two different regimens of chemotherapy-immunotherapy treatments prior to surgery.

Have you been diagnosed with advanced breast, lung, colorectal, or bladder cancer and does your doctor plan to send a sample of your tumor for genetic testing? If so, then you may be able to take part in a research study that looks at whether an expert review of your tumor genetic test results can help your doctor identify better treatment options or clinical trials that may be suitable for your cancer.

Do you have solid tumor of the lung or esophagus? Have the standard treatments for your condition been ineffective or not tolerable? If so, you may be eligible to participate in an early phase research study of the investigational drug YL201 as a possible treatment for advanced solid tumors.

Have you been diagnosed with Hepatocellular Carcinoma (HCC), also referred to as Liver Cancer? If so, you may be a good fit for a clinical trial to evaluate how 3 drugs work in combination, and which dose is the best to treat your disease. The 3 drugs are casdozokitug (casdozo-key-tug), toripalimab (tor-i-pal-i- mab) and bevacizumab (bev-uh-siz-oo-mab).